3 hrs ago
On The Fly: Analyst Initiation Summary
Check below for free stories on KO;KERX;DPS;NBIX;SPN;PEP;CSG;CALD;SYRG;TEVA;VNTV;UBNT;MA;V;TSS;GPN;GDOT;MGI;FLT;HPY;WU;CORR the last two weeks.
7 hrs ago
JPMorgan Chase Initiates Coverage on Keryx Biopharmaceuticals
Keryx Biopharmaceuticals opened at 7.66 on Wednesday. Keryx Biopharmaceuticals has a 1-year low of $1.36 and a 1-year high of $9.98.
Fri Jun 07, 2013
GSK, AZN, KERX, and RPTP Early Briefing and Review
Major drug manufacturers in the U.S., as well as globally, have been facing increasing competition from generic drug makers following the expiration of patents for several blockbuster drugs.
Tue Jun 04, 2013
Solid Showing At WCN Conference For Keryx: Catalysts Still To Come
Keryx Biopharmaceuticals presented additional details from its pivotal Phase III study for Zerenex Monday at the World Congress of Nephrology meeting during a lunch presentation.
Mon Jun 03, 2013
Hedge Funds Are Buying Keryx Biopharmaceuticals
In today's marketplace, there are many gauges investors can use to track publicly traded companies.
Thu May 30, 2013
Keryx: Attractive In Front Of Catalyst-Rich Second Half
Shares of Keryx Biopharmaceuticals continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to break out.
Fri May 24, 2013
A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013
With a potential U.S. market for Chronic Kidney Disease and End Stage Renal Disease patients of almost $1bb, based on 5mm CKD patients above age 65, of whom ~50% are in stage 3-5, there is ample opportunity for a few under-appreciated stories focusing on this market to see real traction as we head into 2H/13. I've highlighted a few of the more ... (more)